Regulatory approval is not commercial readiness. This is one of the most costly misunderstandings in life sciences, and it affects medtech and biotech platform companies disproportionately.
The path to CE mark or FDA clearance is long, demanding, and rightly so. But the discipline it requires — clinical rigour, regulatory precision, quality systems — does not automatically translate into commercial capability. The skills are different. The stakeholders are different. The questions are different.
Over years of working with medical device and diagnostic companies at various stages of launch preparation, I have found that the same gaps appear repeatedly. Not in the science. Not in the product. In the commercial foundations.
The 10 questions below are drawn from the commercial quick scan framework I use when assessing a company’s go-to-market readiness. They are not exhaustive. But if a leadership team cannot answer most of them with confidence, there is work to do before launch day.
1. Do you understand your market environment beyond the clinical problem?
Market size, growth trends, regulatory landscape, and healthcare system dynamics all shape what is commercially possible. Knowing the incidence rate of the condition your technology addresses is the start, not the finish, of market understanding.
2. Have you mapped your full decision-making unit, not just your clinical champion?
In medtech and diagnostics, the person who wants your technology and the person who approves the budget are rarely the same. Surgeons, lab directors, procurement teams, and finance all play a role. If you have only spoken to the clinical enthusiast, you have only spoken to one voice in a much longer conversation.
3. Is your product positioned within a coherent portfolio logic?
How does your device or platform fit within the broader ecosystem your customer already operates in? Does it complement existing workflows, or does it require behaviour change? Portfolio fit affects adoption speed and the strength of your commercial story.
4. Does your value proposition speak differently to each stakeholder?
A value proposition that works for a surgeon will not work for a procurement committee. Clinical benefit, cost-effectiveness, and operational simplicity are different arguments for different audiences. If your messaging sounds the same regardless of who is in the room, it is probably landing with none of them.
5. Do you know your competitive landscape well enough to price and position confidently?
Standard of care is always a competitor, even when no direct product exists. Understanding what your customer currently uses and what they currently pay is the foundation of a credible competitive position. Benchmarking against analogous technologies in adjacent markets is equally important.
6. Have you defined the economic case from the buyer’s perspective, not just your own?
What does adoption cost the customer, and what does it save them? The financial argument must work for hospitals, lab managers, and payers on their own terms: budget cycles, cost centres, procurement thresholds. A compelling economic case is not built on your revenue model. It is built on their financial reality.
7. Is your revenue model stress-tested against real market conditions?
Direct sales, distributor partnerships, capital plus consumable models, licensing: each carries different margin structures, adoption timelines, and organisational requirements. The right model depends on your market, your stage, and your internal capability. High-level projections are a starting point, not a plan.
8. Do you have a structured sales channel strategy, not just a distribution assumption?
Which accounts will you target first and why? What does the buyer journey look like from initial interest to signed order? Who manages the relationship after the sale? Commercial readiness means having answers to these questions before you need them, not while you are trying to close your first deal.
9. Is your marketing communications plan built for your audience, not your technology?
Scientific publications and conference presentations build credibility. They do not build commercial pipelines on their own. A structured communications plan covering KOL engagement, stakeholder-specific messaging, and a pre-launch awareness strategy is the bridge between clinical validation and commercial momentum.
10. Is your operational framework ready to support commercial launch, not just regulatory approval?
Regulatory clearance is a milestone, not a commercial strategy. Manufacturing scalability, supply chain reliability, logistics, and post-market support all need to be in place before launch, not after. The companies that stumble after approval are usually the ones who treated operations as a post-regulatory problem.
hese questions are not a checklist to complete once and file away. They are a diagnostic. The honest value comes from sitting with the ones you cannot answer clearly.
In practice, I use a structured scoring approach across each of these dimensions, assessing where a company stands against best-in-class commercial preparation. The gaps that emerge almost always point to the same underlying issue: commercialisation was treated as something to address after the science was settled.
It rarely is. The commercial conversations with buyers, with procurement, with the people who control budget need to start earlier than feels comfortable. The companies that have those conversations early build a fundamentally different quality of go-to-market strategy than those that start them under the pressure of an imminent launch.
If you are preparing for a commercial launch and want an honest assessment of where you stand, the Bioventa commercial quick scan is a structured way to find out. It covers each of the areas above in depth and produces a clear picture of where your commercial foundations are strong and where the real work lies.
Bioventa works with medtech, diagnostics, and biotech platform companies on commercial strategy, go-to-market readiness, and team building. If you would like to explore a commercial quick scan or discuss your launch readiness, reach out directly via info@bioventa.be
© 2026 Bioventa BV | All rights reserved | Terms of use | Privacy Policy | Cookie Policy
